Alpha-Mannosidosis Market

The global alpha-mannosidosis (AM) market accounted for USD 12.78 billion in 2023 and is expected to reach at USD 81.54 billion by 2034 with a CAGR of 18.35% during the forecast period 2024-2034. The market will grow due to factors such as growing awareness of alpha-mannosidosis, regulatory approvals and incentives for rare disease therapies, advancements in the AM treatment landscape, an increasing emphasis on orphan drugs and reimbursement strategies, and emerging therapeutic modalities.

New therapeutics for Alpha-Mannosidosis are being developed as a result of increased financing for research and cooperation between government agencies, pharmaceutical corporations, and academic institutions. The main goals of the research are to comprehend the mechanisms behind disease, pinpoint therapeutic targets, and create novel forms of treatment such as gene therapy, substrate reduction therapy, and enzyme replacement therapy (ERT). For instance, Sarepta Therapeutics reported encouraging outcomes from the ESSENCE study, which assessed SRP-9001 for Duchenne muscular dystrophy, in March 2022.

By treatment type, the enzyme replacement therapy segment accounted for the highest revenue-grossing segment in the global alpha-mannosidosis (AM) market in 2023 owing to the increasing adoption of enzyme replacement therapy (ERT) as a standard of care, favorable reimbursement policies, and a growing patient pool seeking effective disease management options. For instance, Orchard Therapeutics reported in March 2022 that patient recruitment in the registrational study of OTL-203 for MPS-I was complete. Additionally, the gene therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in gene editing technologies, promising preclinical and clinical trial results, and increasing investment in gene therapy research and development for Alpha-Mannosidosis.

By indication, the type 1 segment accounted for the highest revenue-grossing segment in the global alpha-mannosidosis (AM) market in 2023 owing to the prevalence of Type 1 Alpha-Mannosidosis, higher diagnosis rates, and the availability of targeted treatments specifically tailored for this disease subtype. For instance, REGENXBIO Inc. stated in March 2022 that Phase 1/2 data for RGX-121 in Mucopolysaccharidosis Type II (MPS II) would be presented at the World Symposium. Additionally, the type 3 segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of Type 3 Alpha-Mannosidosis, improved understanding of its clinical manifestations, and rising demand for therapeutic interventions targeting this specific subtype.

By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global alpha-mannosidosis (AM) market in 2023 owing to the high patient admission rates for specialized care, availability of advanced diagnostic and treatment facilities, and the central role hospitals play in managing rare diseases like Alpha-Mannosidosis. For instance, Amicus Therapeutics reported encouraging topline data in February 2022 from the Phase 3 PROPEL trial, which assessed AT-GAA in late-onset Pompe disease. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on personalized and specialized care, rising demand for comprehensive disease management, and the expansion of specialty clinics offering tailored treatments for Alpha-Mannosidosis patients.

North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, high awareness about rare diseases, significant investment in research and development, and favorable reimbursement policies for Alpha-Mannosidosis treatments. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing patient population, improving healthcare infrastructure, rising awareness about rare diseases, and growing investment in healthcare research and development in the Asia Pacific region. For instance, Sanofi stated in March 2022 that it had completed the acquisition of AstraZeneca's RSV-nAb monoclonal antibody program.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Treatment Type, Indication, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: Alpha-Mannosidosis (AM) Market Report 2023 - 2034

Alpha-Mannosidosis (AM) Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)

• Enzyme Replacement Therapy
• Bone Marrow Transplant
• Gene Therapy
• Others

Alpha-Mannosidosis (AM) Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)

• Type 1
• Type 2
• Type 3

Alpha-Mannosidosis (AM) Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospitals
• Specialty clinics
• Others

Alpha-Mannosidosis (AM) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA